Rank |
Status |
Study |
1 |
Unknown †
|
Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Condition: |
Healthy Subjects |
Interventions: |
Drug: Lorazepam; Drug: Placebo |
Outcome Measures: |
Correlated Brain Activity using MEG and SNI analysis; Correlated Brain Activity using MEG and standard analyses |
|
2 |
Unknown †
|
Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy
Condition: |
Patient Satisfaction for Bronchoscopy |
Interventions: |
Drug: Lorazepam; Drug: Control |
Outcome Measures: |
patient satisfaction; relationship between patient satisfaction and sleep quality, anxiety level |
|
3 |
Unknown †
|
IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Conditions: |
Schizophrenia; Schizoaffective Disorder; Agitation |
Interventions: |
Drug: IM olanzapine; Drug: haloperidol plus lorazepam IM |
Outcome Measures: |
Positive and Negative Symptom Scale Excited Component (PANSS-EC); Agitation-Calmness Evaluation Scale (ACES) |
|
4 |
Recruiting
|
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Condition: |
Advanced Cancers |
Interventions: |
Drug: Lorazepam; Drug: Placebo; Drug: Haloperidol decanoate; Behavioral: Questionnaires |
Outcome Measure: |
Control of Delirium Symptoms |
|
5 |
Recruiting
|
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
Condition: |
Alzheimer's Disease (AD) |
Intervention: |
Drug: lorazepam |
Outcome Measures: |
AVLT Long term memory score; Groton Maze Learning Test (GMLT) score |
|
6 |
Recruiting
|
Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Conditions: |
Status Epilepticus; Epilepsy |
Interventions: |
Drug: Clonazepam; Drug: Fosphenytoin; Drug: Placebo; Drug: Lorazepam |
Outcome Measures: |
Percentage of patient with a cessation of seizures and absence of recurrence; Duration between the first cessation and the recurrence of seizures; Percentage of patients having had a second injection of benzodiazepine; Percentage of patients having had an injection of the second line treatment; Percentage of patients having a general anesthesia for refractory status epilepticus; Percentage of patients having had a side effect; Percentage of patients having been mechanically ventilated; Glasgow Coma Scale; Mortality; Length of stay in Intensive Care Unit; Length of stay in hospital |
|
7 |
Not yet recruiting
|
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Conditions: |
Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy |
Interventions: |
Drug: Clobazam; Drug: Clonazepam; Drug: Lorazepam |
Outcome Measures: |
Time (measured in minutes) to onset of seizure freedom; Reduction of seizure frequency/minute; Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale; Ambulatory function as measured by the Hauser Ambulation Index |
|
8 |
Recruiting
|
Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
Condition: |
Healthy Volunteers |
Interventions: |
Drug: etifoxine; Drug: lorazepam; Drug: Placebo |
Outcome Measure: |
Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB) |
|
9 |
Recruiting
|
Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly
Condition: |
Volunteers Aged Between 65 and 75 Years Old |
Interventions: |
Drug: etifoxine; Drug: Lorazepam; Drug: Placebo |
Outcome Measure: |
Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB) |
|
10 |
Recruiting
|
Characterizing and Predicting Drug Effects on Cognition
Condition: |
Cognitive Deficits |
Interventions: |
Drug: Topiramate; Drug: Lorazepam |
Outcome Measures: |
Relationship between neurocognitive performance and study drug plasma concentration; Neurophysiological effect of study drug on working memory |
|
11 |
Recruiting
|
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Conditions: |
Liver Fibrosis; Alpha-1 Antitrypsin Deficiency; AAT Deficiency; AATD |
Interventions: |
Device: Abdominal ultrasound; Procedure: History and physical; Procedure: Intravenous catheter; Procedure: Blood draw; Other: Liver questionnaire; Procedure: Liver Biopsy; Drug: Midazolam; Drug: Fentanyl; Drug: Lidocaine; Drug: Acetaminophen; Drug: Lorazepam; Drug: Oxycodone/Acetaminophen; Drug: Ondansetron |
Outcome Measures: |
To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.; To identify environmental and host risk factors for clinically significant liver fibrosis.; To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.; To explore epigenetic markers for the development of liver fibrosis.; To quantify liver fibrosis progression. |
|
12 |
Recruiting
|
Sedative Premedication: Efficacy On Patient Experience
Condition: |
Perioperative Anxiety |
Interventions: |
Drug: Lorazepam; Other: no premedication; Drug: Placebo (microcrystalline celluloses) |
Outcome Measures: |
the EVAN score; the perioperative level of anxiety |
|
13 |
Not yet recruiting
|
Explanation About Sleep in Post Trauma Patients
Conditions: |
Post Traumatic Stress Disorder; Sleep Deprivation |
Interventions: |
Behavioral: Explanation encouraging sleep; Behavioral: Explanation discouraging sleep; Drug: Lorazepam |
Outcome Measure: |
PTSD severity as measured by CAPS |
|
14 |
Recruiting
|
Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability
Condition: |
Dental Care for Disabled |
Interventions: |
Drug: Midazolam Mylan; Drug: Lorazepam Mylan; Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate |
Outcome Measures: |
Level of cooperation of patient when receiving regular dental care; Recording of vital parameters during regular dental care delivery; Level of patient comfort and possible side-effects after dental treatment session |
|
15 |
Recruiting
|
A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
Condition: |
Healthy |
Interventions: |
Drug: PF-06372865 or Placebo; Drug: PF-06372865 or Placebo or Lorazepam |
Outcome Measures: |
Maximum Observed Plasma Concentration (Cmax); Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast); Area Under the Curve From Time Zero to Extrapolated Infinite Time; Apparent Oral Clearance (CL/F); Apparent Volume of Distribution (Vz/F); Plasma Decay Half-Life (t1/2); Area Under the Curve From Time Zero to 24 hours; Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy); Change in Body Sway; Change in Smooth Pursuit; Change in Bond and Lader VAS; Change in Adaptive Tracking; Change in Visual Verbal Learning Test; Change in Pharmaco-EEG |
|
16 |
Unknown †
|
Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Conditions: |
Critical Illness; Mechanical Ventilation Complication |
Interventions: |
Procedure: Enteral Sedation (EN); Procedure: Control group: Intravenous Sedation (IV) |
Outcome Measures: |
Percent of efficacy, measured by observed RASS = desired RASS ± 1.; Sedation protocol effectiveness: percentage of "protocol violation days" on the total of ICU days.; Delirium and coma free days (respectively negative CAM-ICU and RASS > - 3 in all daily observations until 28° ICU day) (11); Ventilation free days (12); Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13); Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.; Sedative drugs costs.; Indirect inefficacy markers |
|
17 |
Recruiting
|
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Conditions: |
Alcohol Withdrawal Delirium; Alcohol Withdrawal Associated Autonomic Hyperactivity; Alcohol Withdrawal Hallucinosis; Alcohol Withdrawal-Induced Delirium Tremens |
Interventions: |
Drug: Dexmedetomidine; Drug: Placebo |
Outcome Measures: |
The length of ICU stay defined as the time between randomization and ICU transfer orders.; The number of delirium-free and ventilator-free days during the first 28 days of hospitalization; The length in days of the hospital stay; Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.; Resource utilization costs associated with this hospitalization.; Predefined adverse events; average MINDS score |
|
18 |
Unknown †
|
Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: |
Depression |
Interventions: |
Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY; Drug: PHARMACOTHERAPY |
Outcome Measures: |
Hamilton Depression Rating Scale 21 items (HDRS-21); Mini-Mental State Examination (MMSE 35); UKU - Adverse effects rating scales; Demographical Data Memory (MEDABI-20); Rey Figure; Trail Making Test A; Trail Making Test B; Stroop Test; Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).; Vocabulary WAIS (Weschler Adults Intelligence Scale); Frequency Hospitalization Quotient; Hospital Day Quotient (HDQ) |
|
19 |
Not yet recruiting
|
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: |
Lymphoma, Non-Hodgkin |
Intervention: |
Drug: Standard anti-emetics in conjunction with R-CHOP |
Outcome Measures: |
Complete Response, Acute Phase (Day 1), Cycle 1; Complete Response, Delayed Phase (Days 2 to 11), Cycle 1; Complete Response - Cycle 2 and beyond; No Significant Nausea - Cycle 2 and beyond; Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond; Frequency of common adverse events associated with anti-emetics; Severity of common adverse events associated with anti-emetics |
|
20 |
Recruiting
|
TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
Conditions: |
Cardiac Arrest; Postanoxic Encephalopathy; Status Epilepticus |
Interventions: |
Drug: Anti-epileptic drugs; Other: No anti-epileptic drugs |
Outcome Measures: |
Neurological outcome; Long term outcome |
|